AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Health: Lactobacillus rhamnosus GG is perhaps best known for its beneficial effects on gastrointestinal health. It helps maintain a healthy balance of gut microbiota by competing with harmful bacteria for resources and attachment sites in the intestines. LGG has been studied for its efficacy in preventing and managing various gastrointestinal conditions, including acute infectious diarrhea (such as rotavirus gastroenteritis), antibiotic-associated diarrhea, traveler's diarrhea, inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis), and irritable bowel syndrome (IBS).
Immune System Support: Lactobacillus rhamnosus GG has immunomodulatory properties, meaning it can regulate immune responses. It stimulates the production of certain immune cells and cytokines, which helps strengthen the body's immune defense against infections and reduce inflammation. LGG has been studied for its potential to prevent respiratory tract infections (such as the common cold and flu) and reduce the severity of allergic conditions (such as allergic rhinitis and atopic dermatitis).
Women's Health: Lactobacillus rhamnosus GG may play a role in promoting vaginal health by maintaining a balanced vaginal microbiota and inhibiting the growth of pathogenic bacteria and yeast. It is commonly used in probiotic formulations intended to prevent and manage vaginal infections such as bacterial vaginosis and yeast infections. LGG-containing probiotics may also help prevent urinary tract infections (UTIs) in women by modulating the urogenital microbiota.
Digestive Health: Lactobacillus rhamnosus GG has been studied for its ability to alleviate symptoms of lactose intolerance by aiding in the digestion of lactose. It produces lactase enzyme, which helps break down lactose into simpler sugars that are more easily absorbed by the body. LGG may also help improve symptoms of bloating, gas, and abdominal discomfort associated with lactose intolerance.
Pediatric Health: Lactobacillus rhamnosus GG is safe for use in children and has been extensively studied in pediatric populations. It is commonly used to prevent and manage various pediatric gastrointestinal conditions, including acute infectious diarrhea, antibiotic-associated diarrhea, and infantile colic. LGG-containing probiotics may also help reduce the risk of developing allergies and eczema in infants when given prenatally and postnatally to pregnant women and breastfeeding mothers.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.8 | 0.8 | 0 |
| ADHD | 1.9 | 1.3 | 0.46 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.5 | 0.2 |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.6 | -0.5 |
| Allergies | 1.7 | 1.3 | 0.31 |
| Allergy to milk products | 0.7 | 1 | -0.43 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 2.9 | 4.5 | -0.55 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 3.6 | -0.64 |
| Ankylosing spondylitis | 1.4 | 1.5 | -0.07 |
| Anorexia Nervosa | 1.3 | 2.5 | -0.92 |
| Asthma | 2.5 | 0.2 | 11.5 |
| Atherosclerosis | 0.8 | 0.6 | 0.33 |
| Atrial fibrillation | 1.9 | 0.7 | 1.71 |
| Autism | 5 | 6 | -0.2 |
| benign prostatic hyperplasia | 0.3 | 0.2 | 0.5 |
| Bipolar Disorder | 1.3 | 1.7 | -0.31 |
| Brain Trauma | 0.5 | 0.2 | 1.5 |
| Breast Cancer | 0.4 | 0.4 | |
| Carcinoma | 1.6 | 1.3 | 0.23 |
| Celiac Disease | 3.7 | 1.2 | 2.08 |
| Cerebral Palsy | 0.5 | 1.4 | -1.8 |
| Chronic Fatigue Syndrome | 0.6 | 2 | -2.33 |
| Chronic Kidney Disease | 1.5 | 2 | -0.33 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.9 | 0.11 |
| Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 1.5 | -2 |
| Colorectal Cancer | 0.9 | 0.7 | 0.29 |
| Constipation | 0.9 | 1 | -0.11 |
| Coronary artery disease | 1.1 | 2.1 | -0.91 |
| COVID-19 | 4.1 | 4 | 0.02 |
| Crohn's Disease | 4.8 | 4.8 | 0 |
| cystic fibrosis | 0.5 | 0.2 | 1.5 |
| deep vein thrombosis | 0.5 | 0.8 | -0.6 |
| Depression | 4.9 | 4.2 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.2 | 0.2 | 0 |
| Endometriosis | 1.1 | 0.9 | 0.22 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.1 | 3.3 | -0.06 |
| erectile dysfunction | 1 | 1 | |
| Fibromyalgia | 2.2 | 1.5 | 0.47 |
| Functional constipation / chronic idiopathic constipation | 1.2 | 3.2 | -1.67 |
| gallstone disease (gsd) | 1.1 | 0.9 | 0.22 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.9 | 0.2 | 3.5 |
| Glioblastoma | 0.5 | 0.7 | -0.4 |
| Gout | 0.6 | 0.7 | -0.17 |
| Graves' disease | 0.2 | 1.8 | -8 |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 2.4 | 1 | 1.4 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | -0.2 | |
| Hidradenitis Suppurativa | 0.2 | -0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 1 | -1 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 1.7 | 1 | 0.7 |
| Hyperlipidemia (High Blood Fats) | 0.6 | -0.6 | |
| hypersomnia | 0.8 | 0.7 | 0.14 |
| hypertension (High Blood Pressure | 2.3 | 3.3 | -0.43 |
| Hypothyroidism | 0.8 | 2.8 | -2.5 |
| Hypoxia | 0.6 | -0.6 | |
| IgA nephropathy (IgAN) | 0.7 | 0.8 | -0.14 |
| Inflammatory Bowel Disease | 2.3 | 2.2 | 0.05 |
| Insomnia | 1.2 | 0.3 | 3 |
| Intelligence | 1.1 | 0.5 | 1.2 |
| Intracranial aneurysms | 1 | 1.3 | -0.3 |
| Irritable Bowel Syndrome | 2.4 | 2.6 | -0.08 |
| Liver Cirrhosis | 3 | 1.8 | 0.67 |
| Long COVID | 4.3 | 6.2 | -0.44 |
| Low bone mineral density | 0.9 | 1 | -0.11 |
| Lung Cancer | 1.1 | 1.7 | -0.55 |
| ME/CFS with IBS | 0.2 | 0.2 | 0 |
| ME/CFS without IBS | 0.2 | 0.6 | -2 |
| Metabolic Syndrome | 5.2 | 5 | 0.04 |
| Mood Disorders | 5.2 | 6 | -0.15 |
| multiple chemical sensitivity [MCS] | 1.1 | -1.1 | |
| Multiple Sclerosis | 2 | 3.1 | -0.55 |
| Multiple system atrophy (MSA) | 0.2 | 1.7 | -7.5 |
| myasthenia gravis | 0.2 | 0.2 | |
| Neuropathy (all types) | 1.3 | 0.6 | 1.17 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.5 | 0.6 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.3 | 0.13 |
| Obesity | 6.4 | 4.5 | 0.42 |
| obsessive-compulsive disorder | 2.2 | 3 | -0.36 |
| Osteoarthritis | 1.4 | 1.4 | |
| Osteoporosis | 1.4 | 1.1 | 0.27 |
| pancreatic cancer | 0.9 | -0.9 | |
| Parkinson's Disease | 1.8 | 5.5 | -2.06 |
| Polycystic ovary syndrome | 1.8 | 0.4 | 3.5 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.7 | 0.2 | 2.5 |
| primary biliary cholangitis | 1 | 1 | |
| Psoriasis | 1.1 | 1.6 | -0.45 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 3.5 | -0.21 |
| Rosacea | 0.5 | 0.4 | 0.25 |
| Schizophrenia | 1.9 | 2.9 | -0.53 |
| scoliosis | 0.9 | 0.9 | 0 |
| sensorineural hearing loss | 0.5 | -0.5 | |
| Sjögren syndrome | 1.7 | 1.6 | 0.06 |
| Sleep Apnea | 0.9 | 1.8 | -1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | -0.3 | |
| Stress / posttraumatic stress disorder | 2.2 | 1.4 | 0.57 |
| Systemic Lupus Erythematosus | 2.4 | 2 | 0.2 |
| Tic Disorder | 0.9 | -0.9 | |
| Tourette syndrome | 0.3 | 0.6 | -1 |
| Type 1 Diabetes | 2.3 | 0.6 | 2.83 |
| Type 2 Diabetes | 4.3 | 4.2 | 0.02 |
| Ulcerative colitis | 3.3 | 2.7 | 0.22 |
| Unhealthy Ageing | 1.9 | 0.5 | 2.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.